The United States' orthopedic stem cell market was the fastest growing orthopedic biomaterial segment in the U.S. in 2014, according to an iData Research report.
Here are five key trends in the market:
1. The market grew by more than 17 percent in 2014.
2. The aging population is a driver for stem cell therapies, as it is for the orthopedic market in general.
3. Cell-based therapies are generally very costly, and this may hinder the market.
4. NuVasive led the U.S. orthopedic stem cell market in 2014.
5. NuVasive purchased the Osteocel line of products from Osiris Orthopedics in 2008. The purchase was to complement their strong spinal hardware business.